- Home
- SRG vs ADCT Comparison
SRG vs ADCT Comparison
Compare SRG & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SRG | ADCT |
|---|---|---|
| Founded | 2014 | 2011 |
| Country | United States | Switzerland |
| Employees | 5 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 146.4M | 136.1M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | SRG | ADCT |
|---|---|---|
| Price | $2.43 | $1.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.75 |
| AVG Volume (30 Days) | 171.2K | ★ 796.4K |
| Earning Date | 05-14-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 30.86 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $81,357,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $66.49 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 14.85 |
| 52 Week Low | $2.28 | $0.78 |
| 52 Week High | $4.56 | $4.98 |
Technical Indicators
Market Signals| Indicator | SRG | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 44.16 | 39.75 |
| Support Level | $2.30 | $1.03 |
| Resistance Level | $2.74 | $1.17 |
| Average True Range (ATR) | 0.09 | 0.07 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 63.64 | 37.25 |
Price Performance
Historical ComparisonAbout SRG Seritage Growth Properties
Seritage Growth Properties is principally engaged in the ownership, development, redevelopment, management, sale, and leasing of diversified retail and mixed-use properties throughout the United States.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).